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Abstract
Enterotoxigenic Escherichia coli (ETEC) and Enterohemorrhagic Escherichia coli (EHEC) 
are major food‐ and water‐borne pathogens that constitute a serious public health threat 
in low‐income and developed countries, respectively. Survival and expression of viru‐
lence genes in the human digestive tract are key features in bacterial pathogenesis, but 
the mechanisms behind these processes remain largely unknown due to obvious pro‐
hibition of human studies. Use of well‐controlled and multi‐parametric in vitro models 
can aid in addressing knowledge gaps in ETEC and EHEC pathogenesis. After a general 
description of the physiopathology of ETEC and EHEC infections, this chapter will give 
an overview of all the in vitro studies that have investigated the effect of the main physi‐
cochemical and biotic parameters of the human gut on pathogen survival and expression 
of virulence factors. We bring a picture of how ETEC and EHEC are able to adapt to each 
of the successive environments of the human gastrointestinal tract by reading many cues 
provided by both the host and the gut microbiota.
Keywords: enterotoxigenic Escherichia coli (ETEC), enterohemorrhagic Escherichia coli 
(EHEC), survival, virulence genes expression, human gastrointestinal tract, in vitro 
models
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1. Introduction
Since its identification in 1885, Escherichia coli (E. coli) has become one of the most com‐
prehensively studied bacterial species. While E. coli is widely found in the environment 
and foods and is an important member of the commensal microbiota of mammals, some 
strains have evolved to include pathogenic mechanisms that cause significant diseases in 
humans and animals. In humans, E. coli strains can cause diverse enteric/diarrheagenic or 
extra‐intestinal infections by means of virulence factors that affect a wide range of cellular 
processes. Pathogenic E. coli associated with gastrointestinal illness have been divided into 
eight pathotypes based on their virulence profiles: (i) enteropathogenic E. coli (EPEC), (ii) 
enterohaemorrhagic E. coli (EHEC), (iii) enterotoxigenic E. coli (ETEC), (iv) enteroinvasive 
E. coli (EIEC), (v) enteroaggregative E. coli (EAEC), (vi) diffusely adherent E. coli (DAEC), 
(vii) adherent invasive E. coli (AIEC) and (viii) Shiga toxin‐producing enteroaggregative 
E. coli (STEAEC) [1]. This chapter will cover only two of them: ETEC and EHEC, which show 
opposite trends during their pathogenic processes. Even if in both cases human infections 
are primarily acquired through consumption of contaminated food products or drinking 
water, ETEC is a major cause of infantile diarrhea in developing countries, while EHEC is 
one of the main E. coli pathotypes associated with food poisoning outbreaks in the devel‐
oped world.
To cause human illness, pathogenic enteric E. coli must not only survive the passage through 
the human gastrointestinal (GI) tract but also accomplish their pathogenic process by a com‐
plex and coordinated multistage strategy, including adherence to the host intestine and toxin/
virulence protein production. The current chapter will provide a state of the art of ETEC and 
EHEC physiopathology, then focus on pathogen survival in the human digestive tract and 
regulation of virulence determinants by GI cues. As studies on humans are ethically incon‐
ceivable and small animal models do not recapitulate human pathogenesis, we will introduce 
the potential of dynamic in vitro digestion systems for increasing our understanding of ETEC 
and EHEC pathogenesis in a physiologically relevant GI environment.
2. Physiopathology of ETEC and EHEC infections
2.1. Epidemiological data
ETEC are a significant cause of watery diarrhea in developing countries where sanita‐
tion and clean water remain scarce and a main cause of traveler’s diarrhea [2]. In contrast, 
EHEC are a major public health concern of developed countries [3] (Figure 1). Hence, ETEC 
are among the top four pathogens causing moderate to severe diarrhea among children 
in Africa and South Asia, while EHEC are the third most common zoonotic pathogen in 
Europe associated with large food poisoning outbreaks in EU, the USA, Canada, and Japan. 
The most common serogroups implicated in outbreaks and sporadic cases are O6, O78, O8, 
O128, and O153 for ETEC and O157:H7, O26:H11, O45:H2, O103:H2, O111:H8, O121:H19, 
and O145:H28 for EHEC.
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ETEC cause approximately 280 million episodes of diarrhea worldwide, leading to hundreds 
of thousands of deaths per year [4]. With regard to EHEC, it is estimated that the pathogen 
is responsible for 2,801,000 acute illnesses, 3890 cases of haemolytic and uremic syndrome 
(HUS), 270 cases of permanent end‐stage renal disease, and 230 deaths worldwide [3]. For 
both pathogens, infants less than 5 years old are a high‐risk population. ETEC are respon‐
sible for 20–25% of diarrhea in young children, mostly in low‐income countries, and up to 
40% of traveler’s diarrhea [5]. In developing countries, children suffer from diarrhea attacks 
7–8 times a year, with a peak incidence occurring between 6 and 18 months, and ETEC strains 
are responsible for one of each three attacks [6, 7]. In such countries, ETEC infections have 
then shown to play a significant part in the complex association between malnutrition and 
repeated bouts of diarrheal illness among young children. The impact of EHEC is also greater 
in infants and children, compared to other ages with 42% of cases of HUS and 29% of deaths 
occurring in children between the ages of 0 and 4 years [3].
While the lack of ongoing monitoring systems makes it difficult to understand ETEC pathogenesis 
worldwide, dedicated surveillance systems of human EHEC infections have been developed in 
most of the industrialized areas of the world [8]. In Europe, the surveillance of EHEC infections is 
embedded in the Food and Waterborne Diseases and Zoonoses (FWD) surveillance system coor‐
dinated by the European Center for Disease Prevention and Control (ECDC). FWD is a passive 
surveillance system, collecting data on EHEC infections including laboratory‐confirmed cases, 
probable cases, and possible cases. Cases of HUS are specifically recorded through a network of 
pediatric nephrologists and infection‐control practitioners on the basis of clinical diagnosis.
Figure 1. ETEC and EHEC pathogenesis including epidemiological data on the infections and at‐risk populations, 
reservoir, mode of transmission and virulence factors of the pathogen, and clinical signs are described. A/E: Attaching 
and effacing; CFTR: cystic fibrosis transmembrane regulator; GC‐C: guanylyl cyclase C; GM1: monosialoganglioside 
receptor; LT: heat‐labile enterotoxins; ST: heat‐stable enterotoxins; Stx: Shiga toxin.
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2.2. Reservoir and route of transmission
Both ETEC and EHEC infections are typically acquired through the ingestion of contami‐
nated food or water (Figure 1). However, a major difference between ETEC and EHEC is that 
ETEC only have a human reservoir of infection while EHEC are zoonotic pathogens [2, 9]. 
The main source of ETEC infection is contaminated water, such as surface water and drinking 
water (especially for weaning food) suffering from a lack of adequate sanitation and sewage 
facilities [2]. Nevertheless, a variety of food items including vegetables and herbs imported 
from endemic countries have also been recently implicated in uncommon sporadic cases or 
outbreaks in industrialized countries. Ruminants, especially cattle, are a natural reservoir of 
EHEC, and hence entry into the food chain through fecal contamination. Food (mainly under‐
cooked beef products, unpasteurized milk, and vegetable) and water are the principal sources 
of human contamination with EHEC. Person‐to‐person transmission of EHEC may signifi‐
cantly contribute to outbreaks from a primary source, whereas this mode of transmission is 
not likely under most circumstances for ETEC infection.
The infective dose widely differs between ETEC and EHEC. It fluctuates between 108 and 1010 
cells for ETEC in adults, but vulnerable populations such as infants may be susceptible to 
infection at lower doses [7, 10]. The infective dose for EHEC is recognized to be much lower: 
less than 50 to a few hundred organisms are usually sufficient to lead to the clinical signs [11].
2.3. Clinics and treatments
ETEC or EHEC show similar clinical pictures at the beginning of infections: watery diar‐
rhea leading to rapid dehydration, usually associated with nausea, vomiting, and abdominal 
cramps [2, 11]. With regard to ETEC, following an incubation period of 10–72 hours, the dura‐
tion of illness is typically 3–5 days, and resolved usually without antimicrobial treatment, even 
though symptoms can persist for 2–3 weeks. ETEC infections are generally self‐limited and 
cannot be distinguished from Cholera on clinical grounds. Symptoms are much more severe 
in children from developing countries where diarrhea and malnutrition combine to form a 
vicious cycle leading to declining health status and death. Unlike ETEC, EHEC infections 
may evolve toward extra‐digestive complications. EHEC infections typically progress from 
watery to bloody diarrhea and resolve within a week or 10 days in the majority of infected 
individuals. Nevertheless, in 5–7% of cases, the infection may lead to life‐threatening compli‐
cations, namely HUS and thrombotic thrombocytopenic purpura (TTP), and death [11, 12]. 
HUS is characterized as a triad of acute kidney failure, microangiopathic hemolytic anemia, 
and thrombocytopenia, and remains the most common cause of acute renal failure in children 
in the EU and US. The elderly mostly develop TTP, which differs from HUS because of neu‐
rological symptoms including lethargy, severe headache, convulsions, and encephalopathy.
Currently, treatment for ETEC and EHEC infections consists primarily of supportive ther‐
apy, with oral rehydration to prevent dehydration and loss of electrolytes. For EHEC, gen‐
eral supportive measures also include peritoneal dialysis or hemodialysis and management 
of anemia with transfusion of whole blood or packed red cells [13]. Conventional antibiotic 
treatment is generally not recommended for EHEC‐infected patients as it increases HUS or 
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neurological complications [14]. The use of antimicrobials is also problematic during ETEC 
infection since an etiologic diagnosis cannot be made rapidly, mainly in childhood diarrhea [2]. 
Fluoroquinolones are shown to be effective during ETEC traveler’s diarrhea [15] but should 
be used with caution due to the rise of antimicrobial resistance worldwide and the risk of 
side effects. For both pathogens, antimotility agents can be prescribed but need to be carefully 
administered as they can prolong the residence time of bacteria or their toxins in the intestine.
In this context, alternative prophylactic or therapeutic strategies are currently under develop‐
ment for ETEC and EHEC. Vaccines against the pathogens are still not commercially avail‐
able, although vaccine strategies have been developed and used with variable success in 
animal models and/or humans [16, 17]. However, Dukoral®, a vaccine commercialized for 
Vibrio cholerae, can be prescribed to prevent traveler’s diarrhea due to ETEC. Global alterna‐
tive approaches involving dietary supplementation or probiotics have also been considered 
for both ETEC [18, 19] and EHEC [20, 21], with various levels of evidence from in vitro and 
in vivo studies. Other therapeutic options targeting a specific step in bacterial pathogenesis 
have been developed, mainly for EHEC, such as the use of agents that link toxins or block 
their binding at the cell surface [13] or antibodies that inhibit the terminal complement com‐
plex formation [22].
2.4. Virulence factors
After ingestion by humans, ETEC and EHEC pursue a strategy of infection involving coloni‐
zation of the intestinal mucosal surface and production of toxins. The main sites of coloniza‐
tion differ between the two pathogens: from the upper jejunum to the ileum for ETEC [23, 24] 
and terminal ileum and colon for EHEC [25–27]. Notably, EHEC show a preferential tropism 
to the follicle‐associated epithelium (FAE) of small intestinal Peyer’s patches [25, 28], which 
has not been described for ETEC. Even if for both pathogens toxins are clearly identified as 
their main virulence factor, bacterial pathogenesis is not limited to toxin‐mediated effects, 
and a combination of virulence traits is required to make ETEC and EHEC strains fully patho‐
genic to humans. This part describes the main virulence factors that have been identified for 
ETEC and EHEC.
2.4.1. Acid resistance
After being ingested, the pathogens must first breach the acidic barrier of the human stomach 
to reach their intestinal niche. It is well described that E. coli strains have intricate acid resis‐
tance (AR) systems that enable their survival in the harsh gastric environment, the glutamate‐
dependent AR system providing the highest level of acid protection [29]. Such acid resistance 
is a critical virulence trait of the infection, especially for EHEC for which the infectious dose 
is typically very low.
2.4.2. Colonization factors
ETEC adhere to the intestinal epithelium by means of several colonization factors (CFs). More 
than 25 CFs that are antigenically and structurally diverse, have been identified in ETEC and 
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include fimbrial and fimbrillar structures. Among them, seven are generally more prevalent 
than others: CFA/I (colonization factor antigen) and CS1 to CS6 (coli surface antigen) [30]. 
Most CF receptors have not been yet identified, but CFs are thought to bind to glycopro‐
tein conjugates in mucus fraction from the small intestine and on the surface of host cells. 
Non‐fimbrial adhesins such as TibA, a glycosylated autotransporter; Tia, an outer membrane 
protein; and EtpA, which acts as a molecular bridge binding host cell receptors to the tips of 
ETEC flagella, have also been implicated in the pathogenesis [31].
EHEC colonization involves attaching and effacing (A/E) lesions on the enterocytes, which 
are characterized by ultra‐structural changes, including loss of microvilli and intimate attach‐
ment of the bacterium to the cell surface [32]. Genes encoding A/E lesion formation are local‐
ized on a pathogenicity island, the locus for enterocyte effacement (LEE), which encodes a 
bacterial type III secretion system (T3SS). Colonization is mainly mediated by the primary 
adhesin, namely intimin (encoded by eae gene), but other putative adherence factors have 
been described, such as long polar fimbriae—Lpf—or curli [33]. A number of other non‐fim‐
brial EHEC adhesins have been implicated in adhesion including the plasmid‐encoded toxB, 
the chromosomally encoded adhesins Iha, Cah, and OmpA [32, 33].
Mucin‐degrading enzymes, which allow temporary access to intestinal cell membrane and 
promote bacterial adhesion have been recently identified in both ETEC and EHEC. In ETEC, 
YghJ, a mucin‐binding metalloprotease [34] and EatA, a member of serine protease autotrans‐
porters of the Enterobacteriaceae (SPATE) family [35] have been described. In EHEC, one 
protein has been shown to have mucinase activity: StcE, an extracellular zinc metalloprotease 
which specifically recognizes α‐O‐glycan‐containing substrates [36].
2.4.3. Secretion of toxins
Toxins are considered as the main virulence factor for both ETEC and EHEC as they are 
responsible for the main clinical symptoms and/or systemic complications. In ETEC, secre‐
tory diarrheas are mediated through the action of heat‐stable (ST) and/or heat‐labile (LT) 
enterotoxins.
ETEC strains are able to secrete either one or two toxins (LT and/or ST), but it has been shown 
that LT toxin is less likely to cause disease than ST or LT/ST ETEC toxins [7]. LT toxins encoded 
by the eltAB gene are similar in structure and function to Cholera toxin by sharing 80% homol‐
ogy. LT shows an AB5 configuration with a catalytically active LTA subunit and a pentameric ring of LT
B
 subunits responsible for binding and internalization [37]. LT are mainly secreted 
associated with outer membrane vesicles (OMVs) and bind irreversibly to monoganglioside 
(GM1) on the host cell. LT leads to an increase in cAMP that induces cystic fibrosis transmem‐
brane regulator (CFTR) phosphorylation, eliciting massive fluid loss and watery diarrhea. In 
addition to causing diarrhea, LT plays multiple roles in modulating host cell function and 
providing a competitive advantage for ETEC adherence to cultured intestinal epithelial cells. 
ST toxins encoded by the estAB gene are small cysteine‐rich peptides which mimic the human 
hormone guanylin. They are divided into two structural and antigenically distinct groups: 
STa and STb which reversibly bind to guanylyl cyclase C (GC‐C) and sulphatide, respectively 
[37], leading to CFTR activation and diarrhea.
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Shiga toxins (Stx) are produced by EHEC in the lumen of the intestine, and then cross the 
epithelial barrier by poorly described mechanisms to eventually reach their target organs [38]. 
Two toxin families encoded in the genomes of lysogenic lambdoid phages are produced by 
the bacteria, namely Stx1 and Stx2, the latter being associated with the most severe complica‐
tions [39]. Stx contain two major structural subunits, A and B [40]. The B subunit binds to the 
toxin cellular receptor, globotriaosylceramide‐3 (Gb3), expressed on host microvascular endo‐
thelial cell surfaces (kidney, intestine, and brain). This explains the life‐threatening complica‐
tions associated with EHEC infections. The A subunit exhibits an RNA N‐glycosidase activity 
against the 28S rRNA, resulting in inhibition of protein synthesis and cell death.
3. Bacterial survival in the human digestive tract
Bacterial survival in the human GI tract is a key parameter in ETEC and EHEC physiopathol‐
ogy. Nevertheless, how pathogens can survive in the human digestive environment remains 
largely unknown as studies in humans are impossible. For regulatory, ethical, technical, and 
cost reasons, artificial digestive systems are increasingly used as an alternative to in vivo stud‐
ies in humans. Until now, almost no data are available for ETEC under human digestive 
simulated conditions while a number of studies have assessed the survival of EHEC during 
human in vitro digestion.
Masters et al. [41] have shown that after exposure to pH 2, ETEC became undetectable by 
plate counting after 2 hours. A recent study using flow cytometry analysis indicated that there 
was no significant difference in the percentage of live bacteria when ETEC were subjected to 
pH 5 or pH 7 [42]. Only one study has investigated the impact of 30 g/L bile on the survival of 
ETEC in vitro. Despite the known bactericidal effect of bile in the intestine, growth curves for 
ETEC in Luria Bertani (LB) media and LB‐bile showed similar slopes during the exponential 
growth phase [43].
With regard to EHEC, most of the studies have been carried out, like for ETEC, using simpli‐
fied in vitro approaches integrating a limited number of digestive parameters, such as acid 
pH or bile salts [44, 45]. Even if the pathogen is considered as acid resistant, large variations 
in survival rates have been obtained for E. coli O157:H7 in acidified culture media or in simu‐
lated gastric fluid [45, 46]. This wide range of response may be explained by differences in 
culture conditions, bacterial strains, and pH values used to simulate the gastric phase. Other 
more recent studies have evaluated the survival of EHEC strains by using dynamic multi‐
compartmental in vitro models that closely mimic the gastric, small intestinal, and colonic 
human digestive conditions. In the TNO GastroIntestinal model (TIM), which simulates the 
stomach and the three segments of the human small intestine, it has been shown that EHEC 
survival was affected in the stomach and duodenum (when ingested within a food matrix 
but not with a glass of water), while bacterial growth was observed at the end of digestion 
in the jejunum and ileum [47–49]. This growth renewal in the distal parts of the small intes‐
tine was probably linked to the occurrence of less stringent conditions, such as neutral pH 
and lower concentrations of bile salts due to their reabsorption (as occurred in vivo). EHEC 
survival in the TIM model was found to be strain/serotype dependent [48] and influenced 
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by food matrices [47–49] and age conditions [48]. In particular, thanks to the potential of 
the TIM model, Roussel et al. [49] have shown that differences in digestive physicochemi‐
cal parameters related to age conditions may partly explain the higher susceptibility of chil‐
dren (compared to adults) to EHEC infections and HUS. Additional studies performed under 
human‐simulated colonic conditions (including colonic microbiota) have shown that EHEC 
strains were not able to colonize [50], probably due to the barrier effect of gut microbiota or 
to the high short‐chain fatty acid (SCFAs) concentrations found in the colon and known to 
inhibit EHEC growth [51, 52]. Taken together, these data suggest that the ability of EHEC 
to colonize the human gut would be rather linked to growth renewal of the pathogen in the 
distal parts of the small intestine than the ability to maintain in the colon.
4. Regulation of virulence genes by gastrointestinal cues
To be fully pathogenic, bacteria must not only survive in the human GI tract but also coordi‐
nate expression of virulence determinants in response to localized gut microenvironments. 
An increased number of in vitro or in vivo studies have shown that both ETEC and EHEC 
are able to respond to various GI cues and employ these cues to modulate the expression of 
their virulence factors [33, 53], as described below (Figure 2). Compared to ETEC, where all 
Figure 2. The figure provides a state of the art on the effects of biotic and abiotic parameters of the human gut on ETEC 
and EHEC virulence, as assessed by in vitro studies. Data related to ETEC and EHEC are surrounded by light grey and 
dark grey, respectively. A/E: Attaching and effacing; AI: autoinducer; CFA: colonization factor antigen; CS: coli surface; 
EA: ethanolamine; elt: heat‐labile enterotoxin encoding gene; est: heat‐stable enterotoxin encoding gene; etpA: ETEC 
two‐partner protein A encoding gene; GM1: monosialoganglioside receptor; IhA: IrgA homologe adhesion encoding 
gene; LEE: locus for enterocyte effacement; lpf: long polar fimbriae encoding gene; LT: heat‐labile enterotoxins; NO: nitric 
oxide; SCFA: short‐chain fatty acids; Stx: Shiga toxin; T3SS: type 3 secretion system.
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the available studies have been performed in simple in vitro digestive conditions, recent data 
have been obtained for EHEC in more physiological conditions simulated by dynamic multi‐
compartmental models.
4.1. Regulation by physicochemical parameters of the human gut
4.1.1. pH
Once ingested, pathogens are exposed to the host digestive tract characterized by acid con‐
ditions in the stomach where pH gradually decreases during digestion from around 6 to 2, 
followed by pH close to neutrality in the small intestine.
For ETEC, the release of ST seems to be not pH‐dependent [54], while it is acknowledged that 
extracellular pH has an influence on the release of LT toxin which increases with alkalinity 
[55, 56]. ETEC seems to use the pH gradient in the GI tract to modulate LT toxin production 
and secretion: when bacteria reach the small intestine, alkaline pH induces both transcription 
and maximal release of LT [42].
For EHEC, House et al. [57] have examined, using DNA microarrays, the gene expression 
profiles of EHEC O157 that had been acid stressed and then neutralized relative to the same 
unstressed strain. Virulence factors associated with adhesion, motility, and type III secretion 
were significantly modulated leading to enhancement of motility and host cell adhesion. The 
T3SS genes encoding proteins that mediate colonization and infection in the large intestine 
were downregulated following acid stress [33, 57]. Impact of low pH on Stx gene expression 
and production is not yet fully understood: House et al. [57] have shown no change whereas 
other studies have revealed that acid pH decreases Stx production [58, 59]. In the gastric and 
small intestinal TIM model, Roussel et al. [49] have shown that stx1 and stx2 genes were 
upregulated in the gastric compartment even if Stx‐mediated cytotoxicity is generally associ‐
ated with distal parts of the small intestine or large intestine. Higher expression levels were 
observed under child digestive conditions compared to adult ones where less acidic condi‐
tions are found, which is in accordance with the results of Yuk et al. [58] and Huang et al. [59].
4.1.2. Bile
Once the small intestine is reached, bile salts form a major challenge to pathogens, with bile 
concentrations sequentially decreasing from duodenum to colon due to reabsorption.
Chatterjee and Chowdhury [60] have shown in vitro that 2 g/L crude bile can prevent the 
binding of LT toxin to GM1 and that this effect was associated to arachidonic, linoleic, and 
oleic unsaturated fatty acids detected in crude bile. The same authors demonstrated in vivo 
in rabbit ileal loops that linoleic acid prevented LT‐mediated fluid accumulation in a dose‐
dependent manner [60]. In another study by Nicklasson et al. [61], 1.5 g/L crude bile and 2 g/L 
bile salts sodium deoxycholate and sodium glycocholate‐induced in vitro the expression of 
CS5‐encoding gene csfD. A global transcriptional analysis of two ETEC strains showed that 
bile salts at a concentration of 30 g/L in LB medium upregulated estA, eltA, or etpA (encoding 
for STa, LTa enterotoxins, and EtpA, respectively) while csoA and cstA (encoding for CS1 and 
Enterotoxigenic and Enterohemorrhagic Escherichia coli: Survival and Modulation of Virulence in the Human...
http://dx.doi.org/10.5772/intechopen.68309
11
CS3 colonization factors) were downregulated [43]. In this study, the transcriptional response 
to bile salts was strain‐dependent, suggesting that the results should not be extrapolated to 
the entire pathovar without further investigation. Finally, at the protein level, 1.5 g/L bile salts 
were required for surface expression of at least CS5, CS7, CS8, CS12, CS14, CS17, and CS19 
[62–64]. Haines et al. [62] have shown that bile salts seem not to be required for the expres‐
sion of CS1, CS2, and CS3, while the opposite was demonstrated by Sjoling et al. [63]. These 
results suggest that both interaction of LT toxin with its receptor and expression of ETEC 
colonization factors may be differentially induced along the human intestine where bile acid 
concentrations range from 2 to 20 g/L.
Studies have also shown that bile may serve as an environmental cue for EHEC by modu‐
lating the expression of specific virulence factors [33]. DNA microarray analysis of EHEC 
O157:H7 treated with 1.5 g/L bile salts showed upregulation of acrA and acrB genes encoding 
a bile salts efflux pump [65]. Expression of several other well‐known virulence factors includ‐
ing those encoded on the LEE pathogenicity island, was not altered by bile salt treatment. 
On the contrary, a significant decrease in eae gene transcripts was observed in vitro by other 
authors when 5–8 g/L bile salts were added [66, 67]. Bile salts also modulate the expression of 
other adhesins, such as Lpf: Arenas‐Hernández et al. [68] and Yin et al. [66] found that con‐
centrations of 1.5–5 g/L led to an upregulation of lpf genes. In the TIM system, eae and lpf over‐
expression occurred under child digestive conditions at the end of in vitro digestion, when 
most of the bacterial cells have reached the distal parts of the small intestine [49]. This might 
suggest a higher ability of EHEC to colonize the terminal ileum or colon in children compared 
to adults. Lastly, there is no consensus for the effect of bile salts on stx gene expression. Kus 
et al. [65] reported that 1.5 g/L bile salt downregulated stx2 genes, whereas no influence was 
observed by Hamner et al. [67] with concentrations of 8 g/L.
4.1.3. Digestive enzymes
Very few studies have investigated how human digestive enzymes may influence the expres‐
sion of virulence genes in pathogens, none in EHEC and only two in ETEC. In the latter, 
in vitro studies have shown that trypsin, an endopeptidase secreted by duodenal epithelial 
cells, is able to increase LT release [55] and its secretory activity [69].
4.1.4. Oxygen levels
Various oxygen levels can be found in the human GI tract with concentrations decreasing 
from the upper to the lower digestive tract and from mucosal surfaces to gut lumen. Up to 
date, the effect of various oxygen concentrations on pathogen virulence has been studied only 
in EHEC.
In an in vitro cell culture model, James and Keevil [70] have shown that the presence of oxygen 
enhanced EHEC ability to adhere to epithelial cells. In other recent studies, polarized human 
colon carcinoma cells in a vertical diffusion chamber system were used to investigate the influ‐
ence of reduced apical oxygen levels on EHEC colonization [38] and Stx production [71]. The 
authors demonstrated that both EHEC‐host adhesion and expression and translocation of T3SS 
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effector proteins were increased under microaerobic conditions (1–2% oxygen). Microaerobiosis 
also significantly reduced bacterial growth as well as Stx production and release into the 
medium, while Stx translocation across the epithelial monolayer was enhanced. The role of 
oxygen levels on modulation of EHEC virulence was further confirmed by Lewis et al. [27] 
who showed in in vitro organ culture (IVOC) of human colonic biopsy samples that A/E lesion 
formation was dependent on oxygen levels. These lesions were suppressed under oxygen‐
rich culture conditions routinely used for IVOC. Taken together, these results suggest that the 
microaerobic environment adjacent to the intestinal microvilli may upregulate the expression 
of EHEC virulence factors that promote successful colonization of the large intestine.
4.1.5. Fluid shear
Fluid shear can be defined as distribution of frictional forces due to the hydrodynamic flow 
generated by GI peristaltic activity against the surface of intestinal epithelial cells. In the 
human gut, there is a decreasing gradient of fluid shear stress from mucosa to gut lumen. It 
has been generally assumed that shear stress inhibits pathogen adhesion, thereby serving as 
a non‐specific host defense against bacterial colonization [72]. For both ETEC and EHEC, this 
concept has been very poorly described in the literature.
Tchesnokova et al. [72] have shown, using in vitro erythrocytes and Caco‐2 cell models, a 
shear‐enhanced binding of intestinal CfaE, the tip‐localized minor subunit of CFA/I, in both 
prototypical and clinical ETEC strains. EHEC attachment to host cells is also enhanced by 
levels of shear force similar to peristaltic forces in the intestinal tract, which are required to 
fully activate LEE‐encoded virulence mechanisms [73]. These preliminary data suggest that, 
in addition to a range of chemical environmental signals, ETEC and EHEC are capable of 
sensing and responding to mechanical cues in the human GI tract.
4.2. Regulation by biotic factors of the human gut
4.2.1. Gut microbiota and their metabolites
4.2.1.1. Gut microbiota
During passage through the human gut, enteric pathogenic bacteria such as ETEC and EHEC 
also have to face a high number of commensal bacteria that compete with them for nutrients 
and space. There is scarce data on the interactions of EHEC, but even more so for ETEC, with 
human gut microbiota.
For ETEC, only two studies have investigated gut microbiota changes during ETEC challenge 
[74, 75]. The authors conclude that ETEC infections are associated with a rapid and reversible 
change in gut microbial community structure as well as a significant decrease in overall bacte‐
ria diversity. However, there is no available data on how gut microbiota may influence ETEC 
virulence.
With regard to EHEC, Thévenot et al. [50] have recently shown in an in vitro model of the 
human colon, that E. coli O157:H7 has an individual dependent effect on the colonic micro‐
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biota, as assessed by qPCR analysis on major phyla and genus. The same authors also showed 
that EHEC infection led in the in vitro colonic environment to a significant increase in stx1, 
stx2, and eae expression 9–12 h post‐administration. Besides, it has been also proposed that 
EHEC was sensing autoinducers produced by the GI microbiota, such as the quorum signaling 
molecule AI‐3. EHEC respond to AI‐3 by increasing flagellar synthesis and motility that allow 
the pathogen to more closely approach the mucosal epithelium at the site of colonization [76]. 
On the contrary, other soluble factors secreted by the normal gut microbiota may protect the 
host against EHEC infection. De Sablet et al. [77] have shown, in cecal contents of gnotobiotic 
rats colonized with human microbiota, that small molecules produced in part by Bacteroides 
thetaiotaomicron, a predominant species of the normal human intestinal microbiota, repressed 
stx2 mRNA expression. Mutants of B. thetaiotaomicron with impaired production of a specific 
transporter of vitamin B12 were no longer able to inhibit the production of Stx2 [78]. This work 
suggests that concentration of vitamin B12 in the gut and by extension, activities of commensal 
bacterial species producing and/or consuming vitamin B12, may modulate the production of 
the main virulence factor of EHEC. Other studies have also demonstrated that the interplay 
between the nutrient requirements of normal flora and EHEC is important in determining 
pathogen virulence [76]. Njoroge et al. [79] uncovered the importance of glucose availability 
in regulating T3SS by EHEC: high‐glucose growth media suppressed type III secretion while 
low‐glucose conditions induced LEE expression. EHEC also use fucose that is made available 
from mucus by the microbiota (especially by Bacteroides thetaiotaomicron) to modulate their 
own metabolism and virulence. Pacheco et al. [80] described a novel two‐component system 
that enables regulation of virulence gene expression and carbon‐source choice by EHEC upon 
sensing fucose, resulting in a decrease in LEE transcript levels. All these results tend to indi‐
cate that differential microbiota composition may contribute to host resistance or susceptibil‐
ity to EHEC infections. Then, differences in diet and antibiotic regimens, which cause shifts in 
the composition of the GI microbiota may also influence the outcome of the disease.
4.2.1.2. Short‐chain fatty acids
Several studies have investigated how ETEC and EHEC may respond to gut microbiota 
metabolites such as SCFAs. The three main SCFAs present in the intestine are acetate, propio‐
nate, and butyrate and their concentrations vary from the small intestine to the colon.
A single study with ETEC has shown that addition of SCFAs from C‐2 to C‐7 at a con‐
centration of 2 mg/mL in the culture medium significantly reduced or even abolished LT 
production [81]. A higher number of studies have evaluated how EHEC may sense SCFAs. 
Acetate (10–40 mM) and propionate (2–10 mM) had no effect on Stx2 production levels in 
vitro [78] while acetate production by Bifidobacterium strains was associated with an anti‐
infectious activity through the inhibition of Stx production and translocation [82]. Low 
SCFA concentrations (particularly of butyrate—from 6.25 to 25 mM), more typical of the 
distal ileum, enhanced the expression of EHEC virulence genes involved in motility, adhe‐
sion, and induction of A/E lesion formation [51, 52]. Other studies reported that high con‐
centrations of SCFAs (above 50 mM), typically found in the distal colon, were associated 
with increased expression of T3SS [83] and Iha adhesin [84]. Very recently, Lackraj et al. 
[85] have investigated how EHEC modulate flagella expression and motility in response to 
SCFA mixes typical in compositions and concentrations of the small and large intestines. 
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They showed that when EHEC were exposed to SCFA mixes representative of the small 
intestine, there was a significant upregulation of flagellar genes, flagellar protein FliC, and 
motility, while the opposite was observed with SCFA mixes representative of the large 
intestine. Lastly, a high‐fiber diet, via enhanced butyrate levels, increased host’s expression 
of Gb3 and susceptibility of mice to disease [86]. Conversely, increased levels of microbi‐
ota‐derived acetate protected animals from disease that is caused by the toxin. Collectively, 
these data suggest that molecular cues secreted by commensal microbiota such as SCFAs 
may modulate EHEC motility, adhesion, and toxin production, differently in the small and 
large intestines.
4.2.2. Host hormones
Microbial endocrinology is a newly recognized microbiology research area investigating the 
interactions of bacteria with stress‐associated hormones, such as catecholamine. Among these 
hormones, only epinephrine and norepinephrine have been investigated as environmental 
cues for ETEC and EHEC.
Lyte et al. [87] demonstrated that physiological concentrations of norepinephrine increased 
the in vitro growth of an ETEC strain isolated from calf, as well as the expression of the viru‐
lence factor F5 fimbrial adhesin. On the contrary, Sturbelle et al. [88] did not observe any effect 
of norepinephrine or epinephrine on the in vitro growth of a piglet ETEC strain, and Haines et 
al. [62] found a significant inhibition of porcine ETEC growth by norepinephrine. However, 
a significant increase in motility and expression of F4 fimbriae and LT toxin‐encoding genes 
was shown in the ETEC culture supplemented with conditioned medium (containing auto‐
inducers) and epinephrine [88]. Lastly, Haines et al. [62] found that norepinephrine inhibited 
CFA/I expression in an ETEC strain isolated from humans.
As described for ETEC, Lyte et al. [89] found that norepinephrine increased in vitro EHEC 
growth. EHEC also use norepinephrine as a signal for differential regulation of virulence 
factors mediating invasion, motility, and A/E lesion formation [90]. Regulation of EHEC viru‐
lence by epinephrine and norepinephrine is still not fully understood but it has been shown 
that the pathogen uses the histidine sensor kinases QseC and QseE as sensors of the two hor‐
mones [33, 76]. So, host‐derived hormones epinephrine and/or norepinephrine seem to assist 
ETEC and EHEC in cueing their site of colonization and enhance approach to the epithelial 
layer through increased motility and adhesion.
4.2.3. Other factors
The influence of other GI factors, such as ethanolamine (EA) and nitric oxide (NO), has been 
studied on EHEC virulence, but not on ETEC. However, the nature of the associated regula‐
tions is still not fully understood.
EA comes from the turnover of intestinal epithelial cells and commensal microbiota and is gen‐
erated from the breakdown of phosphatidylethanolamine. EHEC cultured in minimal media 
containing EA showed increased expression of both stx2 and genes encoded on the LEE patho‐
genicity island, as well as a higher number of attaching and effacing (A/E) lesions on host 
epithelial cells [91].
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NO is an essential mediator of the innate immune response of infected colonic mucosa. 
Chemical or cellular sources of NO have been shown to inhibit stx‐ and LEE‐encoded genes 
mRNA expression and Stx synthesis, without altering EHEC viability [92, 93].
5. Conclusion
This chapter shows that we get clearer evidence that the food‐ and water‐borne pathogens 
ETEC and EHEC are able to adapt to each of the successive environments of the human 
GI tract by reading many cues provided by both the host and the gut microbiota. Exposure 
to different environmental cues may impact pathogen survival but also alter the expression of 
virulence genes. Nevertheless, the data obtained until now show many gaps and inconsisten‐
cies. In particular, most of the current studies have been carried out using oversimplified in 
vitro approaches, and what is still missing is the integration of signals delivered in a sequential 
but not in an isolated fashion. Relevant alternatives to better understand how ETEC and EHEC 
respond to these various cues in a temporal‐spatial fashion may imply relevant animal mod‐
els (e.g., human microbiota‐associated animals) [94] or digestion models closely mimicking 
the human digestive tract, such as the TIM or the SHIME (Simulator of the Human Intestinal 
Microbial Ecosystem) [95]. In particular, TIM and SHIME would be of high interest to (i) assess 
how the modalities of ingestion (e.g., infectious dose, growth phase, and food vehicle) and 
age conditions (adult, infant, and elderly) may influence pathogen survival and virulence in 
the human GI tract, (ii) investigate how ETEC and EHEC interact with luminal and mucosal 
gut microbiota under physiological fluid shear stresses and microaerobic conditions, and (iii) 
study host‐microbiota‐pathogen interactions by using intestinal cells in culture coupled with 
TIM or SHIME models, like in the HMI (host microbe interactions) module [96]. For an in‐
depth understanding of pathogen behavior in the human GI tract, these models should be used 
in combination with new technologies such as ‐omics or quantitative imaging technologies.
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